Achilles Therapeutics plc financial data

Symbol
ACHL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
245 Hammersmith Road, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Achilles Therapeutics Ltd (to 2/3/2021)
Latest financial report
6-K - Q2 2024 - Aug 14, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.1M shares +0.37%
Common Stock, Shares, Outstanding 41.1M shares +0.35%
Common Stock, Value, Issued 54K USD 0%
Weighted Average Number of Shares Outstanding, Basic 40.4M shares +1.14%
Weighted Average Number of Shares Outstanding, Diluted 40.4M shares +1.14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.6M USD -1.01%
General and Administrative Expense 4.16M USD -3.57%
Operating Income (Loss) -17.8M USD +1.62%
Nonoperating Income (Expense) 1.43M USD +17.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.4M USD +3.01%
Income Tax Expense (Benefit) 8K USD
Net Income (Loss) Attributable to Parent -16.4M USD +2.77%
Earnings Per Share, Basic -0.41 USD/shares +2.38%
Earnings Per Share, Diluted -0.41 USD/shares +2.38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 95.1M USD -33.8%
Other Assets, Current 2.13M USD -39.7%
Assets, Current 118M USD -32.8%
Deferred Income Tax Assets, Net 41K USD -77.8%
Property, Plant and Equipment, Net 6.95M USD -36.5%
Operating Lease, Right-of-Use Asset 4.17M USD -50.3%
Other Assets, Noncurrent 2.16M USD -31.7%
Assets 131M USD -33.7%
Accounts Payable, Current 2.87M USD -58.4%
Employee-related Liabilities, Current 2.11M USD -12.2%
Accrued Liabilities, Current 7.23M USD -4.55%
Liabilities, Current 14.3M USD -25.2%
Operating Lease, Liability, Noncurrent 258K USD -93.5%
Other Liabilities, Noncurrent 1.16M USD +18.9%
Liabilities 15.7M USD -34.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -14M USD -0.82%
Retained Earnings (Accumulated Deficit) -289M USD -28.5%
Stockholders' Equity Attributable to Parent 115M USD -33.6%
Liabilities and Equity 131M USD -33.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 41.1M shares +0.35%
Common Stock, Shares, Issued 41.1M shares +0.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 95.2M USD -33.8%
Deferred Tax Assets, Valuation Allowance 37.6M USD +12.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.25 pure
Deferred Tax Assets, Gross 37.6M USD +11.6%
Operating Lease, Liability 4.46M USD -48.3%
Depreciation 1.2M USD -7.69%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.2M USD -24.2%
Lessee, Operating Lease, Liability, to be Paid 4.66M USD -49%
Property, Plant and Equipment, Gross 22.1M USD +2.47%
Operating Lease, Liability, Current 4.21M USD -9.69%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.1M USD -67%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.44M USD -48.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 197K USD -61.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.24M USD -59.3%
Deferred Tax Assets, Operating Loss Carryforwards 30.4M USD -13.3%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 418M USD +1.39%
Deferred Tax Assets, Net of Valuation Allowance 41K USD -83.7%
Share-based Payment Arrangement, Expense 1.31M USD -22.9%